Form D · Other

Cambrian Genomics, Inc.

San Francisco, CA · CIK 0001625520

Offering snapshot reported Dec 19, 2014 · SEC filing

Reported sold
$11.2M
Offering amount: $12.5M
Investors reported
109
Form D · investor count
Minimum accepted
$1
Reported outside-investor minimum
First sale
Nov 7, 2014
As reported in this filing

Fundraising history

Reported sold
Reported amount sold by Form D filing date$0$5.61M$11.2MNov 20, 2014: $9,994,393.00Nov 20, 2014Dec 19, 2014: $11,228,392.00Dec 19, 2014

Dates are filing dates, not cash receipt dates. Decreases are reported revisions, not evidence of withdrawals. Separate offering histories are not added together.

What changed?

Latest filing versus its linked predecessor, where available.

  • Reported sold$9,994,393 → $11,228,392
  • Reported investors105 → 109

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Dec 19, 2014Amendment$11,228,392$1,233,999vs Nov 20, 2014109SEC filing
Nov 20, 2014Initial$9,994,393No comparison105SEC filing

Offering details

Securities
Equity
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-228731

Source: Form D, filed Dec 19, 2014. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Austen Heinz Director, Executive
Reese Jones Director

Issuer details

Industry: Other (See others in industry)

Address:
665 3 Rd Street, Suite 425
San Francisco, CA, 94107